Skip to main content

A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Periodic Reporting for period 1 - SenseGuard (A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors)

Reporting period: 2020-04-01 to 2021-03-31

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become the third leading causes of death by 2030. Nevertheless, COPD patients lack of a frequent and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.
To address this massive, worldwide problem, NanoVation’s goal – during the EIC Accelerator project - is to market a clinically validated SenseGuard™. SenseGuard™ is a breakthrough solution, for reliably monitoring of patients with respiratory diseases, including COPD, leveraging a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.
During the 1st year of the project, NanoVation has been finalising the new generation design, while continuing to develop the hardware and software for optimum performance. The company has also been increasing its production capacity, meeting its daily production target. This will continue to be increased throughout the project. NanoVation has commenced the validation activities (including patient recruitment for the clinical trials) which will be the focus of the remaining project period.
Chronic respiratory diseases such as COPD, receive little attention and funding in comparison with other major causes of global morbidity and mortality. Accurate, constant monitoring of COPD patients is crucial to manage exacerbation and minimise outcome severity and costly intervention. Once commercialised, SenseGuard™ will contribute to effective management, therapies and treatment, which will also lead to decreased healthcare costs. By remotely monitoring COPD patients at home, SenseGuard™ will help to reduce admissions in hospitals and thus associated costs for healthcare facilities, thanks to early detection and timely intervention.